For-profit providers still on hot seat in final House COVID report
By
Joe Bush
Dec 12, 2022
Months after its first attack, a key House COVID subcommittee on Friday targeted five of the nation’s five largest for-profit nursing home companies over low staffing and wages and slow vaccine booster...
Study across Genesis facilities finds marked difference in COVID outcomes for boosted residents
By
Alicia Lasek
Dec 08, 2022
Vaccine boosters appeared to play a key role in preventing COVID–19-associated morbidity and mortality across two large LTC systems.
Dementia decline could be slowed by antiseizure meds in some cases, study finds
By
Alicia Lasek
Dec 05, 2022
The results revealed profound early decline among dementia patients with active seizures, including worse cognitive and mental health, and daily functioning.
Clinical briefs for Wednesday, Nov. 23
By
Alicia Lasek
Nov 23, 2022
Groups ask CMS to look into ‘disturbing’ hospice growth in three states … 42 new Alzheimer’s genes discovered in large international study … High blood pressure linked to neurotic personality...
Certain female carriers of Alzheimer’s gene have faster decline than males: study
By
Alicia Lasek
Nov 22, 2022
Women who carry the APOE e4 gene and develop early-onset Alzheimer’s disease may have quicker cognitive decline than men with these attributes, a new study has found.
In major win for insurer, court rules Genesis must absorb costs of multiple COVID suits
By
Kimberly Marselas
Nov 21, 2022
Genesis Healthcare could be on the hook for millions of dollars in potential COVID-19 settlements, following a federal judge’s decision that the skilled nursing giant’s insurer does not have to cover...
Clinical briefs for Monday, Oct. 17
By
Alicia Lasek
Oct 17, 2022
CDC reports higher-than-normal flu cases, upticks in Southeast and South-Central U.S. … Long COVID found among 29% of survivors, women and severely ill most affected … Biden to sign order aiming to...
New model predicts five-year Alzheimer dementia risk
Oct 12, 2022
Model includes demographic information, brain imaging test results, and genetic biomarkers
Common diabetes drug may serve as novel Afib treatment
By
Alicia Lasek
Oct 13, 2022
If approved, it would be the first new drug identified to treat this disease of the heart in a decade, according to Cleveland Clinic researchers.
Glucose-lowering meds compared for use with metformin in T2DM
Oct 03, 2022
Glargine, liraglutide modestly more effective for target glycated hemoglobin levels; microvascular outcomes do not differ materially
